bintrafusp alfa (M7824) / EMD Serono  >>  Phase 1
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bintrafusp alfa (M7824) / EMD Serono
NCT02699515: MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors

Completed
1
114
Japan, RoW
MSB0011359C, M7824
Merck KGaA, Darmstadt, Germany
Solid Tumors
02/22
02/22
EMR 200647-001, NCT02517398: MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

Checkmark P1b data for advanced NSCLC cohorts at ASCO 2018 [screenshot]
Jun 2018 - Jun 2018: P1b data for advanced NSCLC cohorts at ASCO 2018 [screenshot]
Checkmark Data in HPV associated cancers at ASCO 2018 [screenshot]
Jun 2018 - Jun 2018: Data in HPV associated cancers at ASCO 2018 [screenshot]
Completed
1
600
Europe, Canada, Japan, US, RoW
MSB0011359C, M7824
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Solid Tumors
05/22
05/22
INTR@PID 046, NCT04551950: Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer

Completed
1
25
Europe, Japan, US
M7824, Bintrafusp alfa, Carboplatin, Paclitaxel, Bevacizumab, Cisplatin, Radiotherapy
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Cervical Cancer
06/22
06/22
NCT04349280: A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

Hourglass Jul 2022 - Sep 2022 : Data from trial for 2L urothelial cancer
Terminated
1
25
Europe, Canada, US
Bintrafusp alfa
GlaxoSmithKline, Merck KGaA, Darmstadt, Germany
Neoplasms
08/22
08/22
NCT04457778: First in Human Study of M6223

Checkmark Data from trial in combination with M6223 for advanced solid tumors
Oct 2022 - Oct 2022: Data from trial in combination with M6223 for advanced solid tumors
Completed
1
58
Canada, US
M6223, Bintrafusp alfa
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Metastatic Solid Tumors
06/23
06/23
INDUCE-1, NCT02723955: Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors

Completed
1
829
Europe, Canada, Japan, US, RoW
feladilimab (GSK3359609), GSK3174998, Pembrolizumab, Docetaxel, Pemetrexed, Paclitaxel plus Carboplatin, Gemcitabine plus Carboplatin, Fluorouracil (5-FU) plus carboplatin or cisplatin, Dostarlimab, Cobolimab, Bintrafusp alfa
GlaxoSmithKline, Merck Sharp & Dohme LLC
Neoplasms
07/23
07/23

Download Options